Your browser doesn't support javascript.
loading
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC).
Zhou, Di; Byers, Lauren A; Sable, Beate; Smit, Marie-Anne Damiette; Sadraei, Nooshin Hashemi; Dutta, Sandeep; Upreti, Vijay V.
Afiliación
  • Zhou D; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.
  • Byers LA; Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Sable B; Clinical Biomarker, Amgen Inc, Thousand Oaks, CA, USA.
  • Smit MD; Oncology Early Development, Amgen Inc, Thousand Oaks, CA, USA.
  • Sadraei NH; Oncology Early Development, Amgen Inc, Thousand Oaks, CA, USA.
  • Dutta S; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, Thousand Oaks, CA, USA.
  • Upreti VV; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.
J Clin Pharmacol ; 64(3): 362-370, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37694295
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Farmacología Clínica / Carcinoma Pulmonar de Células Pequeñas / Receptores Quiméricos de Antígenos / Neoplasias Pulmonares Idioma: En Revista: J Clin Pharmacol Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Farmacología Clínica / Carcinoma Pulmonar de Células Pequeñas / Receptores Quiméricos de Antígenos / Neoplasias Pulmonares Idioma: En Revista: J Clin Pharmacol Año: 2024 Tipo del documento: Article